The Quantellect read.As of Nov 19, 2026, 18 active firms cover Praxis Precision Medicines Inc: 16 rate it Buy or better, 1 sit at Neutral, and 1 rate it Sell or worse, a buy consensus. The target range is very wide, $162.00 to $1201.00 (about 7.4x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $606.61 sits 99% above the current $304.86. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-3.75 next quarter toward $-9.81 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS18 active firms
Buy
Strong Buy00%
Buy1689%
Neutral16%
Sell16%
Strong Sell00%
Based on 18 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$606.61
+99.0% upside
Average target across 18 active firms as of Nov 19, 2026 vs $304.86 current
Highest Target$1201.00
Average Target$606.61
Lowest Target$162.00
Detailed analyst forecasts for PRAX
Showing 1–18 of 18 named analysts shown · 18 active firms in the rating projection
As of Nov 19, 2026, 16 of 18 active firms rate PRAX a Buy (1 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PRAX EPS & revenue forecast
EPS · NEXT QUARTER
$-3.75
Range $-5.50 – $1.94 · 11 analysts · +17% YoY
Next period, 11 analysts expect Praxis Precision Medicines Inc to earn $-3.75 a share (range $-5.50 – $1.94), versus $-3.20 a year earlier. Full-year consensus is $-13.33, growing to $-9.81 the year after.
REVENUE · NEXT QUARTER
$31.8M
Range $4.0M – $190.1M · 11 analysts
Revenue is expected to reach $31.8M (range $4.0M – $190.1M). Full-year consensus is $567.5K, rising to $331.0M next year.
Top analysts covering Praxis Precision Medicines Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PRAX.
#1
Leonid Timashev
RBC Capital · Rank #27
Buy
$478.00+56.8% to target
Overall win rate
52%
+ Follow
#2
Laura Chico
Wedbush · Rank #55
Sell
$162.00-46.9% to target
Overall win rate
46%
+ Follow
#3
Joel Beatty
Baird · Rank #71
Buy
$400.00+31.2% to target
Overall win rate
50%
+ Follow
#4
Yatin Suneja
Guggenheim · Rank #84
Buy
$800.00+162.4% to target
Overall win rate
50%
+ Follow
#5
Ami Fadia
Needham · Rank #92
Buy
$582.00+90.9% to target
Overall win rate
46%
+ Follow
PRAX stock forecast FAQ
What is PRAX's average 12-month price target?+
The 18 active firms with a live target average $606.61 for Praxis Precision Medicines Inc over the next 12 months, ranging from a $1201.00 high to a $162.00 low, as of Nov 19, 2026.
Is PRAX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 18 active firms as of Nov 19, 2026, 16 rate it Buy or Strong Buy, 1 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PRAX?+
The Street-high target is $1201.00 (HC Wainwright & Co.), and the Street-low is $162.00 (Wedbush). The average of all 18 active-firm targets is $606.61.
How many active Wall Street firms cover PRAX?+
18 active firms have a recognized rating on Praxis Precision Medicines Inc as of Nov 19, 2026, and 18 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PRAX?+
Among analysts who currently cover PRAX, Leonid Timashev of RBC Capital has the strongest overall Quantellect track record (Rank #27). Their current call is Buy with a $478.00 target.
What is Praxis Precision Medicines Inc's projected EPS for next quarter?+
The consensus estimate is $-3.75 per share (range $-5.50 – $1.94) across 11 analysts. Full-year EPS is projected at $-13.33, rising to $-9.81 the following year.
How much revenue is Praxis Precision Medicines Inc expected to report next quarter?+
Consensus revenue is $31.8M (range $4.0M – $190.1M). Full-year revenue is projected at $567.5K, growing to $331.0M next year.
Have analysts been upgrading or downgrading PRAX lately?+
As of Nov 19, 2026, 16 of 18 active firms rate PRAX a Buy (1 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PRAX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.